Drug intelligence / Profile preview

STX-210

Development stage: Preclinical
Lead developer: Styx Biotechnologies
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

STX-210 is an investigational antibody-drug conjugate (ADC) being developed by Styx Biotechnologies for the treatment of solid tumors. The candidate is designed using Styx's proprietary 'AbRefine' AI-driven antibody humanization algorithm and a cleavable linker-payload strategy. While the specific target and payload mechanism of STX-210 remain undisclosed, the program is currently in the discovery stage, with target disclosure and in vivo proof-of-concept data anticipated in late 2026.

Beyond the preview

Go deeper on STX-210.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STX-210.

Explore the full profile